Structure via PubChem · Public domain (PubChem)
ledipasvir
Sign in to saveAlso known as GS5885, GS-5885, GS 5885, WHO 9796
Ledipasvir is a drug for the treatment of hepatitis C that was developed by Gilead Sciences. After completing Phase III clinical trials, on February 10, 2014, Gilead filed for U.S. approval of a ledipasvir/sofosbuvir fixed-dose combination tablet for genotype 1 hepatitis C. The ledipasvir/sofosbuvir combination is a direct-acting antiviral agent that interferes with HCV replication and can be used to treat patients with genotypes 1a or 1b without PEG-interferon or ribavirin.
Chemical data
- Formula
- C49H54F2N8O6
- Molecular weight
- 889 g/mol
- IUPAC name
- methyl N-[(2S)-1-[(6S)-6-[5-[9,9-difluoro-7-[2-[(1R,3S,4S)-2-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]-2-azabicyclo[2.2.1]heptan-3-yl]-3H-benzimidazol-5-yl]fluoren-2-yl]-1H-imidazol-2-yl]-5-azaspiro[2.4]heptan-5-yl]-3-methyl-1-oxobutan-2-yl]carbamate
- SMILES
- CC(C)[C@@H](C(=O)N1CC2(CC2)C[C@H]1C3=NC=C(N3)C4=CC5=C(C=C4)C6=C(C5(F)F)C=C(C=C6)C7=CC8=C(C=C7)N=C(N8)[C@@H]9[C@H]1CC[C@H](C1)N9C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC
- InChIKey
- VRTWBAAJJOHBQU-KMWAZVGDSA-N
- XLogP
- 7.4
- Polar surface area
- 175 Ų
- H-bond donors
- 4
- H-bond acceptors
- 10
- Formal charge
- 0
via PubChem
Research
1,434 papers- Ledipasvir/Sofosbuvir: A Review in Chronic Hepatitis C.Drugs · 2018
- Ledipasvir/Sofosbuvir: a review of its use in chronic hepatitis C.Drugs · 2015
- Ledipasvir-Sofosbuvir: A Once-Daily Oral Treatment Option for Chronic Hepatitis C Virus Genotype 1 Infection.Pharmacotherapy · 2016
- Ledipasvir/sofosbuvir fixed-dose combination for treatment of hepatitis C virus genotype 4 infection.Drugs of today (Barcelona, Spain : 1998) · 2016
- Ledipasvir-sofosbuvir: interferon-/ribavirin-free regimen for chronic hepatitis C virus infection.The Annals of pharmacotherapy · 2015
via PubMed
Wikidata facts
- Mass
- 888.413438
- Has use
- medication
Show 7 more facts
- Commons category
- Ledipasvir
- canonical SMILES
- CC(C)C(C(=O)N1CC2(CC2)CC1C3=NC=C(N3)C4=CC5=C(C=C4)C6=C(C5(F)F)C=C(C=C6)C7=CC8=C(C=C7)N=C(N8)C9C1CCC(C1)N9C(=O)C(C(C)C)NC(=O)OC)NC(=O)OC
- chemical formula
- C₄₉H₅₄F₂N₈O₆
- isomeric SMILES
- CC(C)[C@@H](C(=O)N1CC2(CC2)C[C@H]1C3=NC=C(N3)C4=CC5=C(C=C4)C6=C(C5(F)F)C=C(C=C6)C7=CC8=C(C=C7)N=C(N8)[C@@H]9[C@H]1CC[C@H](C1)N9C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC
- subject has role
- antiviral drug
- medical condition treated
- hepatitis C
- significant drug interaction
- rosuvastatin
Sources (6)
via Wikidata · CC0
~3 min read
Encyclopedic overview
7 sectionsContents
- Medical uses
- Adverse effects
- Interactions
- Mechanism of action
- Cost
- See also
- References
Ledipasvir is a drug for the treatment of hepatitis C that was developed by Gilead Sciences. After completing Phase III clinical trials, on February 10, 2014, Gilead filed for U.S. approval of a ledipasvir/sofosbuvir fixed-dose combination tablet for genotype 1 hepatitis C. The ledipasvir/sofosbuvir combination is a direct-acting antiviral agent that interferes with HCV replication and can be used to treat patients with genotypes 1a or 1b without PEG-interferon or ribavirin.
Ledipasvir is an inhibitor of NS5A, a hepatitis C virus protein.
Excerpted from Wikipedia’s “ledipasvir” article, available under the CC BY-SA 4.0 licence.